S

    SLRX (SLRX)

    Official site

    BIOTECHNOLOGY

    $0.84
    +0.19 (+29.23%)

    Last updated: Jan 07, 2026 at 4:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(24/37)
    Avg Surprise
    -129.00%
    PeriodReportedEst.SurpriseB/MYoY
    Sep 25
    		$-1.81$-1.01-79.21%Miss+84.1%
    Jun 25
    		$-0.45N/A+55.88%Beat+81.0%
    Mar 25
    		$-1.02$-1.03+1.38%Beat-147.8%
    Dec 24
    		$-1.01$-0.74-36.49%Miss-359.1%
    Sep 24
    		$-11.40N/A+98.58%Beat-1653.8%
    Jun 24
    		$-2.37N/A+95.58%Beat-65.7%
    Mar 24
    		$-0.41N/A+93.88%Beat+81.6%
    Dec 23
    		$-0.22N/A+78.22%Beat+92.2%
    Sep 23
    		$-0.65$-1.20+45.83%Beat+73.7%
    Jun 23
    		$-1.43$-1.30-10.00%Miss+36.4%
    Mar 23
    		$-2.23$-2.50+10.80%Beat+31.4%
    Dec 22
    		$-2.83$-2.15-31.63%Miss-25.8%
    Sep 22
    		$-2.47$-2.55+3.14%Beat-23.5%
    Jun 22
    		$-2.25$-2.62+14.12%Beat-28.6%
    Mar 22
    		$-3.25$-2.25-44.44%Miss-116.7%
    Dec 21
    		$-2.25$-2.12-6.13%Miss+10.0%
    Sep 21
    		$-2.00$-1.62-23.46%Miss+20.0%
    Jun 21
    		$-1.75$-1.42-23.24%Miss+46.2%
    Mar 21
    		$-1.50$-1.37-9.49%Miss+72.7%
    Dec 20
    		$-2.50$-2.75+9.09%Beat-468.2%
    Sep 20
    		$-2.50$-2.62+4.58%Beat-242.5%
    Jun 20
    		$-3.25$-4.12+21.12%Beat-69.3%
    Mar 20
    		$-5.50$-11.00+50.00%Beat-102.2%
    Dec 19
    		$-0.44N/A+84.00%Beat+84.0%
    Sep 19
    		$-0.73N/A+73.45%Beat+80.5%
    Jun 19
    		$-1.92$-3.50+45.14%Beat+99.4%
    Mar 19
    		$-2.72$-0.19-1331.58%Miss+99.1%
    Dec 18
    		$-2.75$-0.11-2400.00%Miss+99.0%
    Sep 18
    		$-3.75$-0.21-1685.71%Miss+98.9%
    Jun 18
    		$-312.50$-281.25-11.11%Miss+2.0%
    Mar 18
    		$-287.50$-303.12+5.15%Beat-9.5%
    Dec 17
    		$-287.50$-356.25+19.30%Beat-15.0%
    Sep 17
    		$-337.50$-378.12+10.74%Beat+16.9%
    Jun 17
    		$-318.75$-359.37+11.30%Beat-
    Mar 17
    		$-262.50$-387.50+32.26%Beat-
    Dec 16
    		$-250.00$-462.50+45.95%Beat-
    Sep 16
    		$-406.25$-452.08+10.14%Beat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.66
    SMA 20$0.70
    SMA 50$1.36
    SMA 200$7.19
    EMA 10$0.68
    EMA 20$0.76
    EMA 50$1.54
    EMA 200$6.62

    MACD

    Line: -0.18Signal: -0.25Hist: 0.07

    ADX

    ADX: 26.7+DI: 30.7-DI: 25.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down92.0
    PSAR$0.51

    Bollinger Bands

    Upper Band$0.87
    Lower Band$0.53
    %B Position4961%(Upper)
    Band Width0.90

    RSI (14-Day)

    Neutral
    47.3

    Momentum Oscillators

    Stoch %K43.9
    Stoch %D24.1
    Williams %R-15.0
    ROC (10d)26.0%
    Momentum0.17
    CCI (20d)93.7
    MFI (14d)72.4

    Volatility Measures

    ATR (14d)$0.12(14.2%)
    StdDev (20d)0.09
    Hist Vol159.0%(High)

    Volume Flow

    VWAP$0.81
    OBV207.0M
    AD Line21.3B
    CMF (20d)0.109

    Volume Metrics

    Avg Vol (20d)645.1K
    Vol Ratio9.4x(High)
    VWMA (20d)$0.75

    Pivot Points

    R3$0.84
    R2$0.75
    R1$0.70
    Pivot Point$0.61
    S1$0.56
    S2$0.46
    S3$0.41

    Advanced Oscillators

    TSI-41.95
    Ultimate Osc55.7
    KST-322.13

    Financial Data

    QuarterSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total Revenue$0$0$0$4,426$0$0$0$17,892$0$0$0$0
    Cost of Revenue$1,106$1,106$1,106$2,213$1,105$1,106$1,107$1,105$5,608$1,669$1,669$1,669
    Gross Profit$-1,106$-1,106$-1,106$2,213$-1,105$-1,106$-1,107$16,787$-5,608$-1,669$-1,669$-1,669
    Operating Expenses$894,024$965,565$1.72M$1.49M$1.01M$1.47M$1.77M$970,701$2.53M$3.97M$5.42M$6.48M
    R&D$61,826$116,383$75,532$175,344$137,234$214,447$243,000$59,953$1.04M$2.35M$3.73M$4.69M
    SG&A$833,304$849,182$1.64M$1.31M$869,237$1.25M$1.53M$910,748$1.50M$1.62M$1.70M$1.79M
    Operating Income$-895,130$-965,565$-1,718,695$-1,488,713$-1,006,471$-1,467,517$-1,771,615$-970,701$-2,532,185$-3,971,395$-5,420,663$-6,477,880
    Interest Income$21,663$0$9,162$24,780$34,350$0$56,325$88,905$89,369$0$79,890$92,490
    Interest Expense$0$0$0$0$0$0$0$79,890$0$0$79,890$111,474
    Income Before Tax$-873,467$-957,825$-1,709,533$-1,463,933$-972,121$-1,424,433$-1,715,290$-881,796$-2,442,816$-3,877,308$-5,340,773$-6,370,936
    Income Tax Expense$0$0$0$0$0$4$3$-5$-89,369$-120,416$-79,890$111,474
    Net Income$-873,467$-957,825$-1,709,533$-1,463,933$-972,121$-1,424,433$-1,715,290$-881,796$-2,442,816$-3,877,308$-5,340,773$-6,370,936
    EBITDA$-872,361$-964,459$-1,717,589$-1,487,607$-1,005,366$-1,466,411$-1,770,508$-969,596$-2,526,577$-3,969,726$-5,418,994$-6,476,211
    EBIT$-873,467$-965,565$-1,718,695$-1,488,713$-1,006,471$-1,467,517$-1,771,615$-970,701$-2,532,185$-3,971,395$-5,420,663$-6,477,880
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLRX

    News

    ARMISTICE CAPITAL, LLC Acquires Shares of Decoy Therapeutics Inc (DCOY)

    ARMISTICE CAPITAL, LLC recently acquired 65,503 shares of Decoy Therapeutics Inc (DCOY) at $7.19 per share, representing a new holding for the firm. Since the transaction on June 30, 2026, the stock has declined significantly by 53.69% to $3.33, highlighting the high-risk nature of this pre-clinical biotechnology company with severe financial strain and poor performance indicators. Despite a solid balance sheet rank, the company's lack of revenue and negative profitability make it a speculative investment.

    GuruFocus•8/21/26•
    Neutral

    Armistice Capital (DCOY) discloses 65,503-share, 9.99% holding in Decoy Therapeutics

    Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 65,503 shares of common stock in Decoy Therapeutics Inc. (DCOY), representing a 9.99% stake. This disclosure was made via a Schedule 13G filing with the SEC, indicating that the shares are held through Armistice Capital Master Fund Ltd. with shared voting and dispositive power. The filing specifies that Armistice Capital acts as the investment manager, while Steven Boyd is its managing member.

    Stock Titan•8/14/26•
    Neutral

    Decoy Therapeutics: Q2 Earnings Snapshot

    This article provides a Q2 earnings snapshot for Decoy Therapeutics. No specific financial details or further information are available in the provided content.

    WKYC•8/13/26•
    Neutral

    DCOY Q2'26 Earnings: EPS estimate is (2.88) USD

    Decoy Therapeutics Inc. (DCOY) is projected to announce its Q2'26 earnings on August 14th, with an estimated EPS of (2.88) USD. The company's financial data, including historical and estimated EPS and revenue, is available on TradingView. Earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).

    TradingView•8/13/26•
    Neutral

    Decoy Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

    Decoy Therapeutics Inc. reported its earnings results for the second quarter and six months ended June 30, 2026. For the second quarter, the company posted a net loss of USD 2.37 million, an increase from USD 0.957825 million in the prior year, with basic and diluted loss per share at USD 4.46. For the six-month period, the net loss widened to USD 4.6 million from USD 2.67 million a year ago, with basic and diluted loss per share from continuing operations at USD 8.64.

    www.marketscreener.com•8/13/26•
    Neutral

    Frequently Asked Questions About SLRX

    Does SLRX pay dividends?
    SLRX (SLRX) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In